Terms: = Brain cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Prognosis
4 results:
1. Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.
Takei J; Kamata Y; Tanaka T; Fukasawa N; Gomisawa K; Satake M; Mori R; Yamamoto Y; Suzuki T; Oda A; Murahashi M; Fukuda T; Shimoda M; Murayama Y; Akasaki Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3175-3189. PubMed ID: 37382632
[TBL] [Abstract] [Full Text] [Related]
2. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
[TBL] [Abstract] [Full Text] [Related]
3. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
Neidert MC; Schoor O; Trautwein C; Trautwein N; Christ L; Melms A; Honegger J; Rammensee HG; Herold-Mende C; Dietrich PY; Stevanović S
J Neurooncol; 2013 Feb; 111(3):285-94. PubMed ID: 23263746
[TBL] [Abstract] [Full Text] [Related]
4. Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs.
Song W; Ruder AM; Hu L; Li Y; Ni R; Shao W; Kaslow RA; Butler M; Tang J
PLoS One; 2009 Sep; 4(9):e7157. PubMed ID: 19774073
[TBL] [Abstract] [Full Text] [Related]
